PIMREG and familial pancreatic carcinoma: ROC analysis provided evidence that FAM64A could be developed as a biomarker for the diagnosis of pancreatic cancer, and we found that distinct histologic grades and survival status were associated with FAM64A expression, which suggests a possible relationship between FAM64A expression and survival in pancreatic cancer.